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Abstract
Background: A novel human nuclear receptor interaction protein (NRIP) has recently been
discovered by Chen SL et al, which may play a role in enhancing the transcriptional activity of
steroid nuclear receptors in prostate (LNCaP) and cervical (C33A) cancer cell lines. However,
knowledge about the biological functions and clinical implications of NRIP, is still incomplete. Our
aim was to determine the distribution of NRIP expression and to delineate the cell types that
express NRIP in various malignant tumors and healthy non-pathological tissues. This information
will significantly affect the exploration of its physiological roles in healthy and tumor cells.
Methods: By using tissue microarray (TMA) technology and an anti-NRIP monoclonal antibody
immunohistochemical (IHC) survey, NRIP expression was examined in 48 types of tumors and in
a control group of 48 matched or unmatched healthy non-neoplastic tissues.
Results: Our survey results showed that ten cases were revealed to express the NRIP in six
malignancies (esophageal, colon, breast, ovarian, skin, and pancreatic cancers), but not all of these
specific tumor types consistently showed positive NRIP expression. Moreover, malignant tumors
of the stomach, prostate, liver, lung, kidney, uterine cervix, urinary bladder, lymph node, testis, and
tongue revealed no NRIP expression. Among the control group of 48 matched and unmatched non-
neoplastic tissues, all of them demonstrated IHC scores less than the cut-off threshold of 3. In
addition, ten cores out of thirty-six carcinomatous tissues revealed positive NRIP expression,
which indicated that NRIP expression increases significantly in carcinoma tissue cores, comparing
to the matched controlled healthy tissues.
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localization for this newly identified NRIP expression. In considering the use of NRIP as a potential
diagnostic tool for human malignancies survey, it is important to note that NRIP expression carries
a sensitivity of only 23%, but has a specificity of 100%. There is also a significant difference in positive
NRIP expression between primary carcinomatous tissues and matched controlled healthy tissues.
Although further large-scale studies will merit to be conducted to evaluate its role as a potential
adjunct for cancer diagnosis, data from this study provides valuable references for the future
investigation of the biological functions of NRIP in humans.
Background
Chen et al. cloned a novel human nuclear receptor inter-
action protein (NRIP) gene (GenBankTM accession num-
bers AY766164 [GenBank] and AAX09330 [GenBank])
and deposited it in the National Center for Biotechnology
Information (NCBI) with an unknown function in 2005.
They characterized this human novel gene (NRIP) by
assaying its sub-cellular location in cultured 293T cells,
examining its interaction with some nuclear receptors
(such as AR and GR), and evaluating its trans-activation
activity in distinct promoters. Their results indicated that:
(1) NRIP contains 860 amino acids and its expression is
in the cell nucleus; (2) NRIP binds to both AR and GR and
functions as a nuclear receptor co-activator, so it may be a
transcriptional cofactor of steroid receptors; and (3) by
using a specific NRIP siRNA targeting sequence, it could
knock down endogenous and exogenous NRIP gene
expression, resulting in significantly diminished cell pro-
liferation in prostate (LNCaP) and cervical (C33A) cancer
cells [1,2]. Although NRIP may function to enhance the
transcriptional activity of nuclear receptors, the precise
physiologic role of NRIP is still unclear.
Tissue microarray (TMA) technology has enabled
researchers to investigate multiple specimens simultane-
ously with immunohistochemical (IHC) technology. This
results resulting in a dramatic reduction of time and cost
compared with conventional histopathologic research
techniques. TMA has become a popular tool for tissue-
based research, because it allows for massive acceleration
of studies correlating molecular in situ findings with clin-
ico-pathological information. This approach has become
specifically useful in surveys of tumor populations where
it can be utilized to analyze the functions of newly identi-
fied genes in both healthy and neoplastic human tissues
in both a comprehensive and efficient manner [3-5]. In
order to explore the relationship between NRIP expres-
sion and its biological functions, Chen et al developed
monoclonal antibodies against NRIP [2]. We believe that
further characterization of the subcellular localization of
NRIP expression in various human tissues will signifi-
cantly clarify its physiologic and pathologic roles through-
out the body and help delineate its potential biological
functions. This study is the first comprehensive survey of
NRIP in combined multiple human malignancies, con-
taining somatic, germ line, embryonic tumors and non-
pathological controls in tissue microarray (TMA).
Methods
We evaluated 48 tumor cores and 48 matched and
unmatched non-neoplastic tissue samples using human
tissue microarray technology (US Biomax Inc Catalog No.
BCN962). (Figure 1) Tissue samples were arranged in 12
columns of 8 rows for a total of 96 individual cores (1
mm, 5 μm). All samples of this commercially derived tis-
sue microarray (TMA), originated from different donors.
Researches were blinded to the names and identities of
the specimens and donors. Two board-certified patholo-
gists (CP Han & LF Kao) re-confirmed the histopathologic
features of all of the samples. Of the 48 tumor cores, only
44 contained tumor cells on histopathologic review. The
other 4 clean samples were thought to be missing tumor
components secondary to either inappropriate acquisi-
tion or a processing error during TMA construction.
The 48 cores of labeled neoplastic tissues included speci-
mens from the esophagus, stomach, colon, prostate, liver,
lung, kidney, breast, uterine cervix, ovary, urinary bladder,
lymph node, skin, pancreas, testis and tongue. (Table 1)
The control group of 48 cores of unmatched or matched
non-neoplastic tissue included specimens from the
esophagus, stomach, colon, prostate, liver, lung, kidney,
breast, uterine cervix, ovary, urinary bladder, stomach
lymph node, skin, pancrease, testis, and placenta. Immu-
nohistochemistry and antigen retrieval methods were uti-
lized in the same manner as described in previous
literature [6]. Briefly, the tissue microarray slide, contain-
ing 96 cores of specimens (1 mm, 5 μm in each), was com-
mercially derived from US Biomax Inc. All samples were
washed in xylene to remove the paraffin and then rehy-
drated through serial dilutions of alcohol, followed by
washings with a solution of PBS (pH 7.2). All subsequent
washes were buffered via the same protocol. Treated sec-
tions were then placed in a citrate buffer (pH 6.0) and
heated in a microwave for two 5-minute sessions. The
samples were then incubated with a monoclonal anti-
human NRIP antibody (kindly provided by SL Chen) for
60 minutes at 25°C. The conventional streptavidin perox-Page 2 of 7
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mark) was performed for signal development and the cells
were counter-stained with hematoxylin. Negative controls
were obtained by leaving out the primary antibody. This
slide was mounted with gum for examination and capture
by the Olympus BX51 microscopic/DP70 Digital Camera
System for study comparison.
Although a number of computer-based programs were
designed specifically for the quantitative analysis of IHC,
there still seemed to lack of generally wide acceptance in
research laboratories and clinical practices for evaluation
of the immunoreactivity and histochemical appearance.
Their resultant objective accuracy did not significantly
improved clinical outcome measures, compared with the
conventional analysis by pathologists [7-9]. In this study,
the tissue microarray (TMA) slides were simultaneously
reviewed and scored by 2 qualified pathologists (CP Han
& LF Kao) with agreements, by using a two-headed micro-
scope. IHC nuclear scoring algorithm has not been opti-
mized and standardized, so scores were given based on a
semi-quantitative scoring system developed for this study.
NRIP expression was quantified after evaluating both the
intensity of the reaction and the extent of the reaction. The
intensity of NRIP expression was quantified using the fol-
lowing scores: 0 = negative, 1 = weakly positive, 2 = mod-
erately positive, 3 = strongly positive. The extent of NRIP
expression was quantified by evaluating the percentage of
the positive staining areas in relation to the whole cancer
areas in the core, where a score of 0 was given for 0% reac-
tivity, 1 point was assigned for 1–10% reactivity, 2 points
were assigned for 11–50% reactivity, 3 points were given
for 51–80% reactivity, and samples with >80% reactivity
were assigned a total of 4 points. The final immunoreac-
tive score was determined by multiplying the intensity
score by the extent score, with the minimum score attain-
able being 0 and a maximum score of 12. The 12-tier scor-
ing was also simplified by combining scores 10–12:
strong NRIP expression (+++), 7–9: intermediate NRIP
expression (++), 3–6: weak NRIP expression (+), and 0–2:
negative NRIP expression (-). ROC curve analysis was
used in the selection of the optimal cut-off for determin-
ing threshold for NRIP positivity [10,11]. The cut-off
threshold was set as 3 for this interpretation by the best
sensitivity and specificity (maximum sum of sensitivity
and specificity). Score of 3 points or greater was consid-
ered positive for NRIP expression.
Statistical Methods
Restricted to limited numbers of tissues from a variety of
organ groups, descriptive statistics will be mainly used fol-
lowing our data description. Fisher's exact test was used to
calculate the sensitivity and specificity of NRIP expression
based on results obtained from the study sample and con-
trol group. The sensitivity of NRIP expression is defined as
the proportion of positive NRIP expression among the
known tumor tissues. The specificity of NRIP expression is
defined as the proportion of negative NRIP expression
among the control group of matched and unmatched
non-neoplastic tissue samples.
Results
The study shows that NRIP expression can be detected in
certain types of tumors (Figure 2) Forty-eight tumor cores
were examined from 16 different organs: esophagus,
stomach, colon, prostate, liver, lung, kidney, breast,
uterus, ovary, bladder, lymph node, skin, pancreas, testis,
and tongue. Of the 48 tumor cores, 44 cores revealed
tumor tissue consistent with the histopathologic diagnos-
tic neoplastic labeling after examination by two board-
certified pathologists. The remaining 4 cores (one gastric:
B2, one colonic: C3, and two testicular: O3-4) did not
reveal any cancerous cells on our pathological review.
These 4 tumor-sparing cores of tissues contained normal
organ areas or fibro-adipose components. The IHC stain-
ing results of these 48 cores showed that some types of
specific cancer cells were positive, but others were nega-
tive for monoclonal antibodies raised against human
NRIP. The ID (A-P), organ type, histological diagnosis,
differentiation, IHC scores (0–12) and NRIP expression
status (-, +, ++, +++) are shown in Table 1 for each groups
of cancers.
US Biomax Inc Catalog No. BCN962 Microarray Panel Dis-play (tot l 96 ores)Figure 1
US Biomax Inc Catalog No. BCN962 Microarray 
Panel Display (total 96 cores). A1-3/a1-3: Esophagus, B1-
3/b1-3: Stomach, C1-3/c1-3: Colon, D1-3/d1-3: Prostate, E1-
3/e1-3: Liver, F1-3/f1-3: Lung, G1-3/g1-3: Kidney, H1-3/h1-3: 
Breast, I1-3/i1-3: Uterine cervix, J1-3/j1-3: Ovary, K1-3/k1-3: 
Bladder, L1-3/l1-3: Lymph node, M1-3/m1-3: Skin, N1-3/n1-3: 
Pancreas, O1-5/o1-4: Testis, P1: Tongue, q1-2: Placenta.Page 3 of 7
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expressed in non-neoplastic tissue. NRIP expression was
evaluated in a control group of 48 cores obtained from
matched or unmatched tissue from 16 different organs:
esophagus (a1-3), stomach (b1-3), colon (c1-3), prostate
(d1-3), liver (e1-3), lung (f1-3), kidney (g1-3), breast (h1-
3), Uterine cervix (i1-3), ovary (j1-3), bladder (k1-3),
stomach lymph node (l1-3), skin (m1-3), pancreas (n1-
3), testis (o1-4), and placenta (q1-2). In this preliminary
study, NRIP seemed to be stained weakly in a limited
extent of b1 (normal gastric mucosal epithelium with IHC
score of 1), d1 (normal prostate glandular epithelium
with IHC score 2), g2 (normal renal tubular epithelium
with IHC score of 1), m1 (normal skin squamous epithe-
lium with IHC score of 1, which was restricted to basal cell
layers), and n3 (normal pancreatic acinar epithelium with
IHC score 2). All these IHC scores were beneath the cut-
off threshold of 3, so the NRIP expression results were
Table 1: NRIP expression in 48 cores of tumors in US Biomax BCN962 tissue microarray
ID Organ type Histological diagnosis Differentiation IHC score/NRIP expression
A Esophagus
A1-3 Squamous cell carcinoma Poorly 6/+, 8/++, 0/-
B Stomach
B1 Adenocarcinoma Moderately 0/-
B2 x 0/-
B3 Mucinous Adenocarcinoma Poorly 0/-
C Colon
C1-2 Mucinous Adenocarcinoma Moderately 6/+, 4/+
C3 x 0/-
D Prostate
D1-2 Adenocarcinoma Gleason's grade 3+4 0/-, 0/-
D3 Adenocarcinoma Gleason's grade 4+5 0/-
E Liver
E1-2 Hepatocellular carcinoma Grade II 0/-, 0/-
E3 Hepatocellular carcinoma Grade III 0/-
F Lung
F1-2 Adenocarcinoma Moderately 0/-, 0/-
F3 Squamous cell carcinoma Moderately 0/-
G Kidney
G1-2 Renal cell carcinoma Conventional type 0/-, 0/-
G3 Nephroblastoma 0/-
H Breast
H1-3 Infiltrating ductal carcinoma Grade II 6/+, 0/-, 0/-
I Uterine cervix
I1-3 Squamous cell carcinoma (Keratinized) Moderately 0/-, 1/-, 0/-
J Ovary
J1-3 Serous Adenocarcinoma Grade III 9/++, 12/+++, 0/-
K Urinary Bladder
K1, K3 Transitional cell carcinoma Grade II 0/-, 0/-
K2 Transitional cell carcinoma Grade III 0/-
L Lymph node
L1-3 Large B-cell lymphoma 1/-, 2/-, 0/-
M Skin
M1-2 Squamous cell carcinoma Well 1/-, 0/-
M3 Squamous cell carcinoma Poorly 4/+
N Pancrease
N1, N3 Ductal Adenocarcinoma Poorly 4/+, 0/-
N2 Acinar cell carcinoma 9/++
O Testis
O1-2 Seminoma 0/-, 0/-
O3-4 x 0/-, 0/-
O5 Embryonal rhabdomyosarcoma 0/-
P Tongue
P1 Alveolar rhabdomyosarcoma 0/-
1. IHC scores/NRIP expression: 10–12/+++ (Strong), 7–9/++ (intermediate), 3–6/+ (weak), 0–2/- (negative or low expression not exceed the cut-
off threshold of 3).
2. x: tumor-sparing normal tissuesPage 4 of 7
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of the major indigenous cell types in these healthy non-
pathologic tissues, such as other specific epithelial cells,
endothelial cells, germ cells, blood cells and nerve cells etc
were also stained minimally with IHC score below the cut-
off.
Statistical analysis
NRIP expression was not detected above an IHC score of
3 in any of the matched or unmatched healthy non-neo-
plastic tissue of the control group, resulting in 100% NRIP
expression specificity. However, of the 44 cores of neo-
plastic tissue confirmed by histopathological re-evalua-
tion, only 10 cores of tumor revealed positive NRIP
expression (IHC cut-off score ^ 3). Overall NRIP expres-
sion sensitivity in this group was only 10/44 = 23%.
For subsequent analysis, we also regrouped all of the tis-
sue samples into two categories: hormone-related tumor
and primary carcinoma. Among the 9 hormone-related
tumors, 3 cores of tumor revealed positive NRIP expres-
sion and therefore 33% sensitivity. In the 36 primary car-
cinoma tumor samples, 10 cores of tumor revealed
positive NRIP expression with a comparable sensitivity of
28% for NRIP expression in this subgroup. Fisher's Exact
test showed a p-value of 0.010 (<0.05) between primary
carcinoma tumor and matched controlled tissues. This
indicated that there was a significant difference in positive
NRIP expression between primary carcinoma tissue and
matched controlled healthy tissue cores.
Discussion
Transcriptional regulation by members of the nuclear hor-
mone receptor super-family is a complicated process
requiring the mediation of distinct subclasses of co-regu-
lators. Nuclear receptors function as ligand-inducible
transcription factors. The binding of growth hormonal lig-
and to nuclear receptors can induce receptor dimeriza-
tion, facilitating the ability of the nuclear receptor to bind
to its cognate responsive element and recruit co-regulators
to promote the expression of target genes. NRIP interacts
with nuclear receptors (such as AR and GR), and trans-
activates the distinct promoters in vitro [1,2]. We have
already known that steroid hormones, acting as promot-
ers, were involved in carcinogenic process in some tumor
types, such as breast, ovary, testis, prostate, uterine
endometrium and thyroid [12]. NRIP, acting as one
nuclear transcriptional regulator of the steroid receptors,
may be a critical target for developing diagnostic or thera-
peutic agents against nuclear receptors mediated progres-
sion of some types of cancers.
The tissue microarray (TMA), which facilitates rapid trans-
lation of molecular discoveries to clinical applications,
has become a useful tool in translational research. It also
permits us to complete studies that previously spanned
months and comprised hundreds of whole tissue sections
now in a matter of days on one microscope glass slide
[12,13]. In this study, by using the commercially derived
human tissue microarray (TMA) (US Biomax Inc, Catolog
No. BCN 962), which contained 96 cores including 48
types of primary tumors, as well as 48 matched or
unmatched non-neoplastic controlled tissues, we
attempted to investigate the in situ localization and
expression status of this newly discovered NRIP gene in
various human tissues.
Immunohistochemistry demonstrated NRIP expression at subcellualr nucl ar localizatiFigure 2
Immunohistochemistry demonstrated NRIP expres-
sion at subcellualr nuclear localizations. A, B: esopha-
geal squamous cell carcinoma in core A2 specimen, C, D: 
colon adenocarcinoma in core C2 specimen, E, F: breast ade-
nocarcinoma in core H1 specimen, and G, H: ovarian adeno-
carcinoma in core J2 specimen. A, C, E, G photomicrographs 
were taken in middle-powered, ×200; B, D, F, H photomi-
crographs were taken in high-powered, ×400.Page 5 of 7
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tool in the biomedical and histopathological research.
Although some scoring systems, such as the H-score,
Allred Score etc, have attempted to incorporate both
tumor cell staining percentages and nuclear staining
intensity of estrogen receptor (ER) and progesterone
receptor (PR) into a single total score in breast cancer, the
IHC nuclear scoring analysis algorithm has not yet been
fully optimized for dissimilar biomarkers on various tis-
sue types. Different laboratories may use different scoring
schemes for the nuclear stains. For example, some labora-
tories use only the percentage of positive nuclei as a score
and use different cut-off thresholds of 1%, 5% or 10% for
the interpretation [6-8,14-18]. Instead of the binary posi-
tive-negative end point, we used a 4-point scale (0, 1, 2, 3)
to distinguish the staining intensity. The final IHC score
for this newly discovered NRIP expression in human tis-
sues was calculated by multiplying the average staining
intensity times the percentage of the positive staining
areas in relation to the whole cancer areas. A combination
of 3 or greater was considered positive for NRIP expres-
sion.
The development of tissue microarray (TMA) technology
provides methodology for high-throughput concomitant
analyses of the patterns of newly cloned gene expression
on large numbers of archival tumor and non-tumor tissue
samples. After carefully examining the 96 cores of samples
by two board-certified pathologists (LF Kok and CP Han),
we ascertained that the subcellular compartmentalization
of NRIP gene expression was only restricted to the
nucleus, not in the cytoplasm or cell membrane. This IHC
results provided further evidence to support and demon-
strate Prof. Chen's earlier suggestion that NRIP may be a
nuclear localizing protein.
In this study, we found that some cases of squamous cell
carcinomas or adenocarcinomas can be stained positively
for NRIP, however, others cannot. Not all cases of specific
tumors consistently revealed positive NRIP expression. Of
the 48 cores of tumors from US Biomax BCN 962 TMA,
ten cores of tumors (two cases of esophageal squamous
cell carcinoma, two cases of colon adenocarcinoma, one
case of breast adenocarcinoma and two cases of ovarian
adenocarcinoma, one case of skin squamous cell carci-
noma, one cases of pancreatic ductal adenocarcinoma,
and one case of pancreatic acinar cell carcinoma) revealed
positive NRIP expression. The other 38 tumor cores
including 4 tumor-sparing non-pathological tissues did
not reveal NRIP expression. On the other hand, NRIP was
not expressed in any of the 48 cores of matched or
unmatched controlled non-neoplastic healthy tissues.
Among the 9 steroid hormone related tumors, we found
that one breast and two ovarian cancer tissues showed
positive NRIP nuclear staining, while prostate and testicu-
lar cancer did not. However, after using another tissue
microarray of prostate cancers only, the results showed
positive NRIP nuclear staining in some cases. (Data not
shown)
Based on the results of the study, the sensitivity and spe-
cificity of NRIP expression was calculated in hopes of
delineating the utility of IHC scoring of NRIP expression
as a potential adjunct for cancer diagnosis. The sensitivity
of positive NRIP expression in neoplastic tissues was only
23%, indicating a high false-negative rate. The negative
predictive value was 58.6%, also meaning that if the IHC
NRIP expression is negative, there is still a high probabil-
ity that the cancer tissue diagnosis will be missed. It is pos-
sible that the tissue consists of tumor cells that do not
express NRIP. Hence, NRIP expression may not be a good
IHC tool for cancer screening. The specificity of negative
NRIP expression in non-neoplastic healthy tissues was
100%, indicating a low false-positive rate. The positive
predictive value was also 100%, meaning that if the IHC
NRIP expression is positive, there is a high probability
that the tissue in question is truly neoplastic. Hence, NRIP
expression may be a good IHC tool for cancer confirma-
tion. NRIP's high specificity for cancer cells and high pos-
itive predictive value makes it a useful marker in
confirming the presence of carcinogenic tissue in biopsies
and tissue extractions. Used in conjunction with a thor-
ough history and physical exam, NRIP can be utilized to
as an adjunct to help expediting the diagnosis of cancer.
Our data collectively confirmed that there is a significant
difference in positive NRIP expression between carcinoma
and matched controlled healthy tissues. It is suggested
that NRIP expression to exert its transcriptional activity
might play a role in the carcinogenic process of some
kinds of tumors by exerting transcriptional activity. The
nuclear regulatory protein in neoplastic transforming
process might be changed according to the differentiation
and maturation of the tumor cells. However, before this
relationship can be conclusively delineated, further inves-
tigation of NRIP expression in a larger numbers of cases
and in various types of tumor cells will need to be per-
formed and clinical correlation will need to be deter-
mined.
Conclusion
This is the first study to use a tissue microarray (TMA) and
immunohistochemical (IHC) techniques to investigate
the distribution of newly discovered NRIP expression in
different human neoplastic and normal controlled tissue
types. When using NRIP as a potential diagnostic tool for
human malignancies, the low sensitivity (23%) indicates
there is a high probability that the cancer tissue diagnosis
will be missed. A test with low sensitivity is not useful to
exclude a diagnosis because a less sensitive test will renderPage 6 of 7
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more false-negative results. On the other hand, the high
specificity (100%) of NRIP expression can be used to
ensure that healthy non-neoplastic tissue is not missed. If
the tissue sample has positive NRIP expression, there is
low probability that the tissue is non-neoplastic. In this
study, we demonstrated that some cases of certain types of
carcinoma groups, such as esophageal squamous carci-
noma, colon adenocarcinoma, breast adenocarcinoma,
ovarian adenocarcinoma, skin squamous cell carcinoma,
pancreatic ductal adenocarcinoma, and pancreatic acinar
cell carcinoma express NRIP, while sarcoma, lymphoma,
and germ cell tumor groups did not. All controlled
matched or unmatched non-neoplastic healthy tissues did
not express NRIP. NRIP expression increased significantly
in carcinoma tissues in comparison with healthy controls.
We suggested that NRIP might have a housekeeping func-
tion. Activation of the nuclear NRIP trans-regulatory
effects might play a role in the human carcinogenic proc-
esses. Further large-scale studies designed to determine
whether or not there is an association between nuclear
expressions of NRIP in other human neoplastic tissue is
needed to better delineate its role and association with
neoplastic transformations. By assessing its prognostic
and predictive value, NRIP may be a potential new candi-
date biomarker to identify further therapy targets in the
battle against cancer.
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